# NKT3964

Source: https://onco.cc/drugs/nkt3964/  
OnCo record `nkt3964` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NKT3964 is an experimental protein degrader from NiKang Therapeutics, in phase 1 trials for CCNE1-amplified endometrial and ovarian cancer.

## Summary

NKT3964 is a small molecule PROTAC degrader, oral from NiKang Therapeutics. A selective degrader of CDK2, a cell-cycle enzyme that cancers with extra copies of the CCNE1 gene rely on. The phase 1 study NCT06586957 is recruiting; the company says it is now enrolling people with CCNE1-amplified endometrial cancer. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: NKT3964
- Modality: Small molecule PROTAC degrader, oral
- Mechanism: A selective degrader of CDK2, a cell-cycle enzyme that cancers with extra copies of the CCNE1 gene rely on.

## Sources

- NiKang science and pipeline: https://www.nikangtx.com/science-and-pipeline/
- ClinicalTrials.gov NCT06586957: https://clinicaltrials.gov/study/NCT06586957

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [CDK2](https://onco.cc/targets/cdk2/)
- companies: [NiKang Therapeutics](https://onco.cc/companies/nikang-therapeutics/)
- trials: [A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06586957/)

---
JSON: https://onco.cc/api/v1/entities/nkt3964.json